The present invention relates to a new pharmaceutically acceptable salt, the 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1H-indole-5-carboni- trile citrate, a process for its preparation, pharmaceutical formulations containing said salt and to the use of said active salt in therapy, and particularly to GSK3 related conditions and disorders.